1 study found for:    22915637 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
Imatinib Mesylate or Dasatinib in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia
Interventions: Drug: dasatinib;   Drug: imatinib mesylate;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years